ZA200303734B - A lactonization process. - Google Patents
A lactonization process. Download PDFInfo
- Publication number
- ZA200303734B ZA200303734B ZA200303734A ZA200303734A ZA200303734B ZA 200303734 B ZA200303734 B ZA 200303734B ZA 200303734 A ZA200303734 A ZA 200303734A ZA 200303734 A ZA200303734 A ZA 200303734A ZA 200303734 B ZA200303734 B ZA 200303734B
- Authority
- ZA
- South Africa
- Prior art keywords
- process according
- compound
- lactonization
- solvent
- reaction medium
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 43
- 238000007273 lactonization reaction Methods 0.000 title claims description 27
- 150000001875 compounds Chemical class 0.000 claims description 25
- 239000002904 solvent Substances 0.000 claims description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- 239000012429 reaction media Substances 0.000 claims description 12
- 239000003795 chemical substances by application Substances 0.000 claims description 11
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 6
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 5
- 150000001768 cations Chemical group 0.000 claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- 230000002378 acidificating effect Effects 0.000 claims description 3
- 229910021529 ammonia Inorganic materials 0.000 claims description 3
- 150000003863 ammonium salts Chemical class 0.000 claims description 3
- 239000012296 anti-solvent Substances 0.000 claims description 3
- 238000002955 isolation Methods 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 230000035484 reaction time Effects 0.000 claims description 3
- 125000000217 alkyl group Chemical group 0.000 claims description 2
- 230000032050 esterification Effects 0.000 claims description 2
- 238000005886 esterification reaction Methods 0.000 claims description 2
- 238000010438 heat treatment Methods 0.000 claims description 2
- 239000002184 metal Substances 0.000 claims description 2
- XWLXKKNPFMNSFA-HGQWONQESA-N simvastatin hydroxy acid Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)C(C)(C)CC)C[C@@H](C)C=C21 XWLXKKNPFMNSFA-HGQWONQESA-N 0.000 claims description 2
- 230000002194 synthesizing effect Effects 0.000 claims description 2
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical group ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims 3
- 150000001412 amines Chemical class 0.000 claims 3
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 claims 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 2
- 238000001914 filtration Methods 0.000 claims 2
- 150000008282 halocarbons Chemical class 0.000 claims 2
- 239000003456 ion exchange resin Substances 0.000 claims 2
- 229920003303 ion-exchange polymer Polymers 0.000 claims 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims 1
- 239000004215 Carbon black (E152) Substances 0.000 claims 1
- 150000007513 acids Chemical group 0.000 claims 1
- 150000008280 chlorinated hydrocarbons Chemical group 0.000 claims 1
- 238000002425 crystallisation Methods 0.000 claims 1
- 230000008025 crystallization Effects 0.000 claims 1
- YWEUIGNSBFLMFL-UHFFFAOYSA-N diphosphonate Chemical compound O=P(=O)OP(=O)=O YWEUIGNSBFLMFL-UHFFFAOYSA-N 0.000 claims 1
- 238000001704 evaporation Methods 0.000 claims 1
- 230000008020 evaporation Effects 0.000 claims 1
- 238000000605 extraction Methods 0.000 claims 1
- 229930195733 hydrocarbon Natural products 0.000 claims 1
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- DLYUQMMRRRQYAE-UHFFFAOYSA-N phosphorus pentoxide Inorganic materials O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 claims 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 150000002596 lactones Chemical group 0.000 description 13
- 239000002253 acid Substances 0.000 description 11
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 8
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 6
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 5
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 5
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 5
- 229960004844 lovastatin Drugs 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 5
- 229960002855 simvastatin Drugs 0.000 description 5
- 239000012535 impurity Substances 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000007795 chemical reaction product Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- BUBVLQDEIIUIQG-UHFFFAOYSA-N 3,4,5-tris(phenylmethoxy)-6-(phenylmethoxymethyl)oxan-2-one Chemical compound C=1C=CC=CC=1COC1C(OCC=2C=CC=CC=2)C(OCC=2C=CC=CC=2)C(=O)OC1COCC1=CC=CC=C1 BUBVLQDEIIUIQG-UHFFFAOYSA-N 0.000 description 1
- WMHRYMDGHQIARA-UHFFFAOYSA-N 4-hydroxyoxan-2-one Chemical group OC1CCOC(=O)C1 WMHRYMDGHQIARA-UHFFFAOYSA-N 0.000 description 1
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 1
- 101150085479 CHS2 gene Proteins 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- -1 ammonia cation Chemical class 0.000 description 1
- 230000000326 anti-hypercholesterolaemic effect Effects 0.000 description 1
- 238000010533 azeotropic distillation Methods 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- BOZILQFLQYBIIY-INTXDZFKSA-N mevinic acid Chemical class C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)CCC=C21 BOZILQFLQYBIIY-INTXDZFKSA-N 0.000 description 1
- QLJODMDSTUBWDW-BXMDZJJMSA-N mevinolinic acid Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@@H](C)C=C21 QLJODMDSTUBWDW-BXMDZJJMSA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
Landscapes
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Description
. A LACTONIZATION PROCESS
Antihypercholesterolemic compounds lovastatin and simvastatin are widely used in medicine for the lowering of levels of blood cholesterol.
Those compounds are derivatives of mevinic acid and have the following structural formula (1):
HO, 0
Tr
LA g
R jo}
CH IT H CHs
Hae 0) 15wherein when R = H, the compound is lovastatin and, wherein when R = CH; , the compound is simvastatin.
The chemical structure of both compounds is characterised by the presence of a cyclic lactone moiety (4-hydroxy-3, 4,5, 6-tetrahydro-2H-pyran-2-one group) in 20the molecule. Accordingly, the chemical structure as expressed by the formula (1) may be simplified by the common formula (A),
~~ | WO 02072566 PCT/NL02/00161
HO o
LG SE a 5 wherein Q represents the corresponding remaining part of the molecule of lovastatin and simvastatin.
Both compounds may be produced by the fermentation of various microorganisms or they may be 10prepared synthetically or semi-synthetically by methods known in the art.
Fermentation or synthetic methods for preparing lovastatin or simvastatin usually lead to the formation of a dihydroxyacid form (B) or a salt thereof
HO, OX 1G:
X OH a B) wherein X = H, metal cation, ammonia cation, instead to the desired lactone form (A).
Ammonium salts of the dihydroxyacid form (B) are often used as intermediates in production methods as 25these salts are nicely crystalline. Acid and lactone . forms may also be formed in the mixture.
Whenever this occurs, it is necessary to . convert the intermediate dihydroxyacid form (B) (or, accordingly, a salt thereof) into the desired lactone 30form (A).
Hereafter the dihydroxyacid form (B) of compounds of formula (1) may be denoted as the “statin hd } WO 02/072566 PCT/NL02/00161 - acid” or, if appropriate, “lovastatin acid” or “simvastatin acid” of formula (2):
HO, 6).4 1 ~—OH 0 EY
Ss
CHsy = H CH, (2)
CY
5 . wherein R and X are as hereinabove defined.
Lactonization is a process wherein a hydroxy 10acid loses one molecule of water to form an intramolecular ester - a lactone. This reaction is generally catalysed by an acid; the necessary acidity arises either through the ambient acidity of the substrate itself or by addition of a stronger acid, i.e. 15a lactonization agent to enhance lactonization.
Lactonization is an equilibrium process characterized, in the case of statins, by the following equation:
Dihydroxy acid————p lactone + HO (B) — (A) . 25
In order to obtain a high yield of the lactone, means must be employed to shift the equilibrium to the 30lactone side of the equation.The common means of shifting the equilibrium to the lactone side from (B) to (A) is
SN vo. | WO 02072566 PCT/NL02/00161 : the removal of a reaction product from the reaction mixture. ’ One known way of removal of the reaction product during lactonization of a statin acid is the
S5physical removal of water produced from the reaction mixture, e.g. by means of azeotropic distillation. In this arrangement, the statin acid and/or ammonium salt thereof is heated in a suitable solvent, for example toluene, butyl acetate, ethyl acetate, cyclohexane to a 10boiling point thereof, whereby the azeotropic mixture of the solvent and water having a lower boiling point distills off first and the reaction equilibrium is thus shifted to the formation of the lactone. The speed of water and, optionally, ammonia removal may be increased 15by passing a stream of inert gas through the hot reaction mixture. The ambient acidity of the statin acid is believed to be responsible for the lactonization reaction at these high temperatures.
This process has been disclosed e.g. in US 204444784, US 4582915, US 4820850, US 5159104, WO 98-12188 and many others.
An alternate known possibility (US 5393893) is to perform the lactonization in a two-phase system of an organic solvent, in which the lactone is soluble, and an 25aqueous acid, whereby the water formed is displaced from the organic layer, containing the lactone, to the aqueous layer.
Both alternatives have the disadvantage that elevated temperatures and long reaction times are 30necessary to be applied for completing the reaction, whereby statins are sensitive to heating so that impurities may be formed. , One of the most common impurities arises from dimerization of the starting material. For instance, 35simvastatin of pharmaceutically acceptable quality (e.g. the quality of Ph.Eur. monograph) should contain only less than 0.2 % of such dimer.
Another known method is based on the removal of the lactone itself from the reaction medium. In this of vo. WO 02/072566 PCT/NL02/00161 ; arrangement, the statin acid or its salt is dissolved in a water-miscible solvent in the presence of an acidic ’ catalyst and water is added to the reaction mixture, after a certain reaction period, as an antisolvent. The 5lactone is not soluble in water and separates out from the solution, thus shifting the equilibrium in the solution to allow formation of the next lactone. This method has been disclosed in EP 351918 / US 4916239
This reaction does not require elevated temperatures so 10that the potential for forming impurities, particularly dimers, is lower.
However the selection of the water-miscible solvent and the proper amounts and timings of added water is crucial since fast or premature addition of water can 15lead to serious problems in isolation of the product as impurities of similar structure present in the starting statin acid may accordingly separate from the solution and decrease the purity of the obtained lactone.
In addition, all of the above known lactonization methods 20require reaction times longer than one hour for obtaining an acceptable degree of conversion. This together with the necessary subsequent work-up, makes these methods complicated to carry out and economically undesirable.
According to a first aspect, the present 25invention provides a process for synthesizing a compound of formula (1)
HQ, Oo 104
LA
, CH TT H CHs
Hac S comprising the steps of intramolecular esterification, lactonization, of a compound of formula (2):
y
HO, OX 1& +— OH 0 H
SA
CH3 = H CHs 2)
Hye with a lactonization agent in a suitable solvent thus yielding a reaction medium 10wherein R is a hydrogen atom or a lower alkyl group, preferably a methyl group and X is a hydrogen atom or a cation, wherein the lactonization agent forms a hydrated complex with water, released on the lactonization of compound (2) 15into compound (1), which hydrated complex is substantially insoluble in the solvent.
Optionally, the process also comprises the steps of removal of the hydrated complex after the reaction from the reaction mixture and isolation of the 20compound (1) from the reaction medium, preferably without an aid of an antisolvent.
This lactonization of the statin proceeds at ambient temperature, is simple and short and is easily operable on an industrial scale. . 25Furthermore, the process does not require any special techniques or operations for shifting the equilibrium during the reaction.
Preferred aspects of the present invention are also further defined in the claims.
The starting acid form of simvastatin or lovastatin may be employed in a crude or purified state.
Claims (30)
- : 1.A process for synthesizing a compound of formula (1) HO 0 TrON . _R Q S (1) HaCY comprising the steps of intramolecular esterification, lactonization, of a compound of formula (2): HO OX T= — OH o E rR Q CH, =H CH 2) HyCY with a lactonization agent in a suitable solvent thus yielding a reaction medium wherein R 1s a hydrogen atom or a lower alkyl group, and X is a hydrogen atom or a cation, wherein the lactonization agent forms a hydrated complex with water, released on the lactonization of compound (2) into compound (1), which hydrated complex is substantially insoluble in the solvent.
- 2. Process according to claim 1 wherein R is a methyl group. Amended page 27 July 2004
- 3. Process according to claims 1 or 2 wherein compound (2) 1s subsequently isolated from the reaction medium, and wherein compound (1) is substantially soluble in the solvent.
- 4. Process according to any one of claims 1 to 3 wherein X is a hydrogen atom, a metal cation or an ammonium cation.
- 5. Process according to any of the preceding claims wherein the solvent is substantially inert.
- 6. Process according to any of the preceding claims wherein the solvent is substantially immiscible in water.
- 7. Process according to any of the preceding claims wherein the solvent is a hydrocarbon solvent or a halogenated hydrocarbon or mixtures thereof.
- 8. Process according to any of the preceding claims wherein the solvent is a halogenated hydrocarbon solvent.
- 9. Process according to claim 8 wherein the solvent is a chlorinated hydrocarbon solvent.
- 10. Process according to claim 9 wherein the sclvent is dichloromethane.
- 11. Process according to any of the preceding claims wherein the lactonization agent is an acidic compound.
- 12. Process according to any of the preceding claims wherein the lactonization agent is substantially anhydrous.
- 13. Process according to any of the preceding claims wherein the lactonization agent is selected from one or more of the following: methane sulphonic acid, phosphorus pentoxide, a strongly acidic ion-exchange resin. Amended page 27 July 2004
- 14. Process according to any of the preceding claims wherein the lactonization agent is methane sulphonic acid and/or a strongly acidic ion-exchange resin,
- 15. Process according to any of the preceding claims wherein the lactonization agent binds ammonia upon forming the hydrated complex.
- le. Process according to any of the preceding claims wherein the hydrated complex is removed from the reaction medium.
- 17. Process according to claim 16 wherein the hydrated complex is removed from the reaction medium in a substantially solid form by means of filtration.
- 18. Process according to claims 16 or 17 wherein before the filtration step a base is added to the reaction medium.
- 19. Process according to claim 18 wherein the base is an organic amine.
- 20. Process according to claim 19 wherein the organic amine is a triethylamine and/or pyridine.
- 21. Process according to claim 20 wherein the organic amine is triethylamine.
- 22. Process according to any one of claims 1-17 wherein the hydrated complex is removed from the reaction medium by means of extraction with alkalinized water.
- 23. Process according to any of the preceding claims wherein isolation of compound (1) is carried out without an aid of an antisolvent.
- 24. Process according to any of the preceding claims 3-23 wherein compound (1) is isclated from the reaction medium by crystallization or by evaporation of the reaction medium to dryness. Amended page 27 July 2004
- 25. Process according to any of the preceding claims wherein the compound of formula (2) is the ammonium salt of simvastatin acid.
- 26. Process according to any of the preceding claims wherein the molar ratio between compound (2) and the lactonization agent is roughly 1:1.01 to 1:1.5.
- 27. Process according to any of the preceding claims wherein lactonization of compound (2) proceeds without heating the reaction medium.
- 28. Process according to any of the preceding claims wherein lactonization of compound (2) has a reaction time of between 15 and 60 minutes. ’
- 29. A compound of formula (1): HO 0 0 EH LA CHs H oCH3 ol wherein R 1s a hydrogen atom or a methyl group, obtainable according to any of the preceding claims.
- 30. A pharmaceutical composition comprising a compound of formula (1) according to claim 29."31. A process according to claim 1 substantially as herein described with reference to any one of the illustrative Examples 1 to 4. Amended page 27 July 2004
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ZA200303734A ZA200303734B (en) | 2003-05-14 | 2003-05-14 | A lactonization process. |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ZA200303734A ZA200303734B (en) | 2003-05-14 | 2003-05-14 | A lactonization process. |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200303734B true ZA200303734B (en) | 2004-05-14 |
Family
ID=33453098
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200303734A ZA200303734B (en) | 2003-05-14 | 2003-05-14 | A lactonization process. |
Country Status (1)
Country | Link |
---|---|
ZA (1) | ZA200303734B (en) |
-
2003
- 2003-05-14 ZA ZA200303734A patent/ZA200303734B/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100538674B1 (en) | Process for the production of semi synthetic statins via novel intermediates | |
EP1288212B1 (en) | Process of lactonization in the preparation of statins | |
KR20010074856A (en) | Process for selective lactonization | |
US6562984B2 (en) | Lactonization process | |
ZA200303734B (en) | A lactonization process. | |
RU2214407C2 (en) | Improved method for lactonization in preparing statins | |
KR100423892B1 (en) | A new process of lactonization in the preparation of statins | |
EP1673361B1 (en) | A method for the manufacture of lovastatin | |
WO2006059346A2 (en) | An improved process for lactonization to produce highly pure statins | |
EP1786765B1 (en) | An improved process for lactonization in the preparation of statins | |
BG107477A (en) | A rpocess for lactonization to produce highly pure simvastatin | |
KR100502834B1 (en) | The preparation method of simvastatin by improved process of lactonization and its purification process | |
ES2270722A1 (en) | Method of obtaining amorphous calcium atorvastatin | |
AU2002239155A1 (en) | A lactonization process | |
NZ552342A (en) | An improved process for lactonization in the preparation of statins | |
ES2204285A1 (en) | Procedure is for separation of lovastatin from fermentation source prior to addition of dissolvents and involves adjustment of acid pH in fermentation source to precipitate lovastatin |